Citadel Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-30,557
| Closed | -$158K | – | 10185 |
|
|
2019
Q2 | $158K | Sell |
30,557
-8,791
| -22% | -$39.5K | ﹤0.01% | 8331 |
|
|
2019
Q1 | $142K | Sell |
39,348
-31,418
| -44% | -$136K | ﹤0.01% | 8407 |
|
|
2018
Q4 | $434K | Buy |
70,766
+22,423
| +46% | +$137K | ﹤0.01% | 6625 |
|
|
2018
Q3 | $282K | Sell |
48,343
-17,279
| -26% | -$86.3K | ﹤0.01% | 7674 |
|
|
2018
Q2 | $279K | Sell |
65,622
-32,197
| -33% | -$162K | ﹤0.01% | 7335 |
|
|
2018
Q1 | $432K | Buy |
97,819
+29,061
| +42% | +$130K | ﹤0.01% | 6152 |
|
|
2017
Q4 | $362K | Buy |
68,758
+2,704
| +4% | +$16.5K | ﹤0.01% | 6146 |
|
|
2017
Q3 | $405K | Buy |
66,054
+8,237
| +14% | +$52.1K | ﹤0.01% | 5615 |
|
|
2017
Q2 | $418K | Buy |
57,817
+6,256
| +12% | +$38.5K | ﹤0.01% | 5377 |
|
|
2017
Q1 | $273K | Buy |
+51,561
| New | +$348K | ﹤0.01% | 6018 |
|
|
2016
Q4 | – | Sell |
-80,547
| Closed | -$754K | – | 8166 |
|
|
2016
Q3 | $754K | Buy |
80,547
+36,348
| +82% | +$302K | ﹤0.01% | 4222 |
|
|
2016
Q2 | $279K | Buy |
44,199
+19,820
| +81% | +$127K | ﹤0.01% | 5330 |
|
|
2016
Q1 | $135K | Sell |
24,379
-120,610
| -83% | -$453K | ﹤0.01% | 5887 |
|
|
2015
Q4 | $809K | Buy |
+144,989
| New | +$958K | ﹤0.01% | 3850 |
|
|
2015
Q1 | – | Sell |
-25,040
| Closed | -$447K | – | 9007 |
|
|
2014
Q4 | $447K | Buy |
25,040
+7,517
| +43% | +$93.7K | ﹤0.01% | 4884 |
|
|
2014
Q3 | $176K | Buy |
+17,523
| New | +$212K | ﹤0.01% | 5858 |
|
Other funds holding PETX
Citadel Advisors's PETX Position: Q3 2019 in Review
Citadel Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 30,557 shares — an estimated $158K sold.
Citadel Advisors first reported a position in PETX in Q3 2014 and held it in 16 quarters. The position peaked at $809K in Q4 2015. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.
- Citadel Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
- Citadel Advisors sold 30,557 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $158K.
- Citadel Advisors first reported a position in Aratana Therapeutics, Inc. in Q3 2014 and held it in 16 quarters.
- Citadel Advisors's Aratana Therapeutics, Inc. position peaked at $809K in Q4 2015.
- 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.
Based on Citadel Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.